ICYMI: Trial Begins to Evaluate Savolitinib and IMFINZI for Renal Cell Carcinoma
According to a news release, researchers from biopharmaceutical company HUTCHMED and pharmaceutical company AstraZeneca launched, at the onset of November 2021, the Phase 3 SAMETA clinical trial. During the trial,…